AU2020369137A1 - Methods and compositions for treating sickle cell disease with a ferroportin inhibitor (VIT-2763) - Google Patents

Methods and compositions for treating sickle cell disease with a ferroportin inhibitor (VIT-2763) Download PDF

Info

Publication number
AU2020369137A1
AU2020369137A1 AU2020369137A AU2020369137A AU2020369137A1 AU 2020369137 A1 AU2020369137 A1 AU 2020369137A1 AU 2020369137 A AU2020369137 A AU 2020369137A AU 2020369137 A AU2020369137 A AU 2020369137A AU 2020369137 A1 AU2020369137 A1 AU 2020369137A1
Authority
AU
Australia
Prior art keywords
group
compound
scd
treatment
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020369137A
Other languages
English (en)
Inventor
Franz DÜRRENBERGER
Vania Manolova
Naja NYFFENEGGER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vifor International AG
Original Assignee
Vifor International AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vifor International AG filed Critical Vifor International AG
Publication of AU2020369137A1 publication Critical patent/AU2020369137A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
AU2020369137A 2019-10-22 2020-10-22 Methods and compositions for treating sickle cell disease with a ferroportin inhibitor (VIT-2763) Pending AU2020369137A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962924556P 2019-10-22 2019-10-22
EP19000483 2019-10-22
EP19000483.8 2019-10-22
US62/924,556 2019-10-22
EP20163777 2020-03-17
EP20163777.4 2020-03-17
EP20176336.4 2020-05-25
EP20176336 2020-05-25
PCT/EP2020/079802 WO2021078889A1 (en) 2019-10-22 2020-10-22 Methods and compositions for treating sickle cell disease with a ferroportin inhibitor (vit-2763)

Publications (1)

Publication Number Publication Date
AU2020369137A1 true AU2020369137A1 (en) 2022-04-07

Family

ID=73005635

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020369137A Pending AU2020369137A1 (en) 2019-10-22 2020-10-22 Methods and compositions for treating sickle cell disease with a ferroportin inhibitor (VIT-2763)

Country Status (11)

Country Link
US (1) US20220274973A1 (https=)
EP (1) EP4048262A1 (https=)
JP (1) JP7594004B2 (https=)
KR (1) KR20220086563A (https=)
CN (1) CN114765955B (https=)
AU (1) AU2020369137A1 (https=)
BR (1) BR112022007616A2 (https=)
CA (1) CA3154524A1 (https=)
IL (1) IL291137A (https=)
MX (1) MX2022004806A (https=)
WO (1) WO2021078889A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025535398A (ja) 2022-10-21 2025-10-24 ビフォー （インターナショナル） エージー 二環式フェロポーチン阻害剤
EP4731218A1 (en) 2023-06-26 2026-04-29 Vifor (International) AG Ferroportin-inhibitors for the use in the treatment of hereditary haemochromatosis (hh)
WO2026041650A1 (en) 2024-08-20 2026-02-26 Vifor (International) Ag Ferroportin-inhibitors for the use in the treatment of lupus nephritis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3002416C (en) 2015-10-23 2023-10-24 Vifor (International) Ag Benzimidazolyl derivatives for use as ferroportin inhibitors
US11191818B2 (en) * 2016-08-04 2021-12-07 Takeda Pharmaceutical Company Limited Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome
JOP20180036A1 (ar) * 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
ES2934492T3 (es) 2018-12-13 2023-02-22 Global Blood Therapeutics Inc Inhibidores de ferroportina y métodos de uso

Also Published As

Publication number Publication date
JP2023500060A (ja) 2023-01-04
CA3154524A1 (en) 2021-04-21
IL291137A (en) 2022-05-01
US20220274973A1 (en) 2022-09-01
JP7594004B2 (ja) 2024-12-03
WO2021078889A1 (en) 2021-04-29
KR20220086563A (ko) 2022-06-23
CN114765955B (zh) 2025-06-24
EP4048262A1 (en) 2022-08-31
MX2022004806A (es) 2022-05-16
BR112022007616A2 (pt) 2022-07-12
CN114765955A (zh) 2022-07-19

Similar Documents

Publication Publication Date Title
CN109512805B (zh) 用于治疗水通道蛋白介导的疾病的化合物
AU2020316632B2 (en) Ferroportin-inhibitors for the use in the treatment of transfusion-dependent beta-thalassemia (TDT)
JP7561180B2 (ja) 腎臓損傷の予防及び治療で使用するためのフェロポーチン阻害剤
US20220274973A1 (en) Methods And Compositions For Treating Sickle Cell Disease With A Ferroportin Inhibitor (VIT-2763)
US20250268878A1 (en) Ferroportin-inhibitors for the use in the treatment of myelodysplastic syndromes (mds)
JP7359396B2 (ja) 細胞外ヒストンによって媒介される病理を処置及び予防するための化合物
WO2015069948A1 (en) Novel methods
US20140350097A1 (en) Treatment of hypotension associated with hemodialysis
EA048997B1 (ru) Способы и композиции для лечения серповидно-клеточной болезни ингибитором ферропортина (vit-2763)
CN116710091A (zh) 用于治疗骨髓增生异常综合征(mds)的膜铁转运蛋白抑制剂
EA049341B1 (ru) Применение ингибиторов ферропортина для лечения миелодиспластических синдромов (мдс)
EA048075B1 (ru) Ингибиторы ферропортина для применения при лечении трансфузионно-зависимой бета-талассемии (tdt)
EA047958B1 (ru) Ингибиторы ферропортина для применения с целью предупреждения и лечения повреждений почек
HK1208363B (en) Compounds for use in the treatment of aquaporin-mediated diseases